Gynecomastia is a benign enlargement of male breast tissue driven by hormonal shifts, and it is overwhelmingly more common than male breast cancer. Male breast cancer accounts for less than 1% of all breast cancer cases, while gynecomastia affects males at every stage of life, from newborns to older men. The two conditions share an unfortunate overlap: both tend to show up as a mass behind the nipple, which is exactly why the distinction matters and why many men who notice a breast lump are unsure whether to worry.
How Common Each Condition Actually Is
Gynecomastia is one of the most frequently diagnosed breast conditions in males. A Danish registry study covering 20 years found an average incidence of about 3.4 per 10,000 men per year, with peaks among young men aged 16 to 20 and older men aged 61 to 80, and the rates in both groups climbed dramatically over the study period.1The Journal of Clinical Endocrinology & Metabolism. Marked Increase in Incident Gynecomastia: A 20-Year National Registry Study, 1998 to 2017 Among adolescents, a large cross-sectional study of over 530,000 boys found that about 70% of pubertal gynecomastia cases occurred at ages 13 to 14.2Frontiers in Pediatrics. Pubertal gynecomastia incidence among 530,000 boys: a cross sectional population based study Those registry numbers capture only clinically diagnosed cases; many mild instances go unreported. Estimates of lifetime prevalence, including subclinical breast tissue growth, run much higher.
Male breast cancer, by contrast, is genuinely rare. Population-based data show that its incidence rate has remained relatively stable over recent decades, unlike female breast cancer, which has shifted more noticeably.3PubMed Central. Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer The rarity of male breast cancer is precisely what makes it dangerous: men and their doctors often do not think of it as a possibility, which can delay diagnosis.
What Each Condition Feels Like
Gynecomastia typically presents as a soft-to-rubbery, somewhat tender disc of tissue centered directly beneath the nipple. It is often symmetrical, affecting both sides, though one side can be more prominent. The tenderness itself is a clue: gynecomastia in its active growth phase frequently hurts or aches when pressed, especially early on. The swelling fans outward from the nipple in a gradual, diffuse pattern.4PubMed. Mammographic appearances of male breast disease
Male breast cancer has a different character. About three-quarters of the time, it shows up as a painless, firm lump that sits off-center from the nipple.5PubMed Central. Male Breast Cancer Presenting as Nipple Discharge That eccentric location is one of the more reliable clinical differences. The mass itself tends to feel hard and fixed rather than rubbery and mobile. It may be accompanied by skin changes like puckering or retraction, nipple inversion, or swollen lymph nodes in the armpit. Nipple discharge is uncommon in men generally, but when it does occur, it demands attention: one center found that more than half of men presenting with nipple discharge had an underlying malignancy, compared with roughly one in six women presenting with the same complaint.6PubMed Central. Male Breast Cancer Presenting as Nipple Discharge
Red Flags That Warrant Further Workup
Not every lump behind the nipple needs imaging or biopsy. A bilateral, soft, symmetrical mass centered on the nipple in a teenager or in someone taking a known offending medication is almost always gynecomastia. Diagnostic evaluation becomes necessary when a palpable mass is unilateral, hard, fixed to surrounding tissue, located away from the nipple, or accompanied by nipple discharge, skin changes, or swollen underarm nodes.7PubMed Central. Mammography Findings of Male Breast Diseases
It is also worth distinguishing both conditions from pseudogynecomastia, which is simply fat deposited in the chest area without any real glandular growth. On exam, pseudogynecomastia shows diffuse breast fullness but no firm subareolar nodule. These patients generally need reassurance rather than investigation.8Mayo Clinic Proceedings. Gynecomastia: Pathophysiology, Evaluation, and Management
How Imaging Tells Them Apart
Mammography and ultrasound are the main tools for sorting out male breast lumps. Gynecomastia has a characteristic look on a mammogram: a fan-shaped density radiating outward from the nipple, blending into the surrounding fat. In advanced or long-standing cases, the tissue can become dense enough to resemble a female breast pattern.9PubMed. Mammographic appearances of male breast disease
Male breast cancer looks quite different in most cases. It tends to appear as an irregular mass positioned off-center from the nipple, sometimes with spiculated edges or small calcifications.10PubMed. Radiography of gynecomastia and other disorders of the male breast The trouble is that cancer does not always play by those rules. Some male breast cancers have a rounder, well-defined appearance that can mimic a benign process. For that reason, most solid masses found on imaging in men still require a tissue sample to be certain.11PubMed. Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond
Biopsy and Tissue Diagnosis
When imaging raises any doubt, a core needle biopsy is the standard next step. The procedure uses a larger-gauge needle than a simple fine-needle aspiration, giving pathologists a better chunk of tissue to evaluate. In a study of male breast lesions, core needle biopsy achieved a sensitivity of about 99% and a specificity of 100% for detecting malignancy, with essentially no false positives.12PubMed. Is core needle biopsy effective at diagnosing male breast lesions? That accuracy makes it a reliable way to distinguish gynecomastia from cancer without jumping straight to surgery.13PubMed Central. Core needle biopsy in male breast lesions
When male breast cancer is confirmed on biopsy, the vast majority of cases turn out to be invasive ductal carcinoma. In one study, about 87% of male breast cancers were this subtype, with various less common patterns making up the rest.14American Journal of Clinical Pathology. Male Breast Cancer: A Single-Institution Clinicopathologic and Immunohistochemical Study Another series found invasive ductal carcinoma in roughly 71% of cases, with most tumors falling into hormone-receptor-positive categories.15PubMed Central. Male breast carcinoma: a clinicopathological and immunohistochemical characterization study That hormone-receptor positivity has direct treatment implications, which we will get to below.
Does Gynecomastia Raise Your Cancer Risk?
This is the question most men with gynecomastia actually want answered, and the evidence is reassuring. While both conditions involve breast tissue responding to hormones, gynecomastia itself does not appear to be a stepping stone toward cancer. Gynecomastia tissue occasionally shows atypical cell changes under the microscope, but a study examining those changes found that the atypical ductal hyperplasia sometimes seen in gynecomastia specimens did not lead to breast cancer.16Iranian Red Crescent Medical Journal. Incidence of Atypical Change and Risk of Breast Cancer in Patients with Gynecomastia
That said, the underlying conditions that cause gynecomastia can sometimes also raise cancer risk through a shared mechanism. The clearest example is Klinefelter syndrome, a genetic condition where males carry an extra X chromosome. Men with Klinefelter syndrome frequently develop gynecomastia because of their altered hormone balance, and they also face a substantially elevated risk of breast cancer. Across large cohorts, the standardized incidence ratio for breast cancer in Klinefelter syndrome is roughly 18 times higher than in the general male population.17PubMed Central. The incidence of male breast cancer in Klinefelter Syndrome and its proposed mechanisms The mortality ratio is even more striking, running close to 58 times higher overall, and far higher still in certain chromosomal subtypes.18Journal of the National Cancer Institute. Cancer Incidence and Mortality in Men with Klinefelter Syndrome: A Cohort Study Even so, these risks remain well below the breast cancer rates seen in women, countering the notion you sometimes see in case reports that Klinefelter patients face female-level risk.19PubMed Central. Breast Cancer Risk Among Klinefelter Syndrome Patients
The point is that gynecomastia and breast cancer can coexist in a person with an underlying hormonal condition without one condition causing the other. The hormone imbalance is the shared upstream driver. Having gynecomastia on its own, without an underlying hormonal disorder or genetic predisposition, does not meaningfully raise breast cancer risk.
Genetic Risk Factors for Male Breast Cancer
BRCA gene mutations are best known for their role in female breast and ovarian cancers, but they also matter for men. BRCA2 mutations carry the stronger association with male breast cancer. One large study estimated the cumulative risk of breast cancer by age 70 at roughly 6.8% for male BRCA2 carriers, compared to about 1.2% for BRCA1 carriers.20Journal of the National Cancer Institute. Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers In a clinical series of male BRCA mutation carriers, breast cancer was the second most common cancer seen, and every case occurred in someone carrying a BRCA2 variant. Those tumors tended to be high grade and hormone-receptor positive, but the patients generally did well with treatment.21PubMed Central. Male BRCA mutation carriers: clinical characteristics and cancer spectrum
This has practical implications. Men with a family history of BRCA-associated cancers, particularly breast cancer in close male or female relatives, benefit from genetic counseling. A JAMA Oncology review confirmed that there is convincing evidence of increased breast, prostate, and pancreatic cancer risk in male BRCA carriers, and that these risks should inform screening decisions.22JAMA Oncology. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review Gynecomastia, by contrast, has no meaningful genetic testing implications. It results from hormonal fluctuations and rarely signals anything worrisome at the DNA level.
What Causes Gynecomastia in the First Place
Gynecomastia develops when the balance between estrogen and androgen activity in breast tissue tips toward estrogen. This happens at predictable stages of life: in newborns (from maternal hormones), during puberty (when estrogen production temporarily outpaces testosterone), and in older age (as testosterone levels fall). Those three peaks account for most cases, and the majority resolve on their own or require minimal intervention.23PubMed. Gynecomastia and hormones
Medications are another major trigger. A systematic review identified 49 different drugs associated with gynecomastia.24PubMed Central. Gynecomastia and drugs: a critical evaluation of the literature The drugs most definitively linked include spironolactone (a blood pressure and heart failure drug), cimetidine (an older heartburn medication), ketoconazole (an antifungal), estrogen-containing therapies, anti-androgens, and 5-alpha reductase inhibitors used for prostate enlargement or hair loss. Additional medications with probable associations include risperidone, certain calcium channel blockers, omeprazole, some HIV medications, anabolic steroids, and opioids.25PubMed. Drug-induced gynecomastia: an evidence-based review When gynecomastia tracks closely with the start of a medication, stopping or switching the drug often resolves the problem.
Treatment Paths Are Very Different
This is where the two conditions diverge most sharply. Gynecomastia that is recent (under about 12 months) and still in its active phase sometimes responds to tamoxifen, an estrogen-blocking drug. In a small double-blind crossover trial, seven out of ten patients saw their gynecomastia shrink with tamoxifen, and all four who had painful breast tissue got relief.26PubMed. Treatment of gynecomastia with tamoxifen: a double-blind crossover study Once gynecomastia has been present for more than a year, the tissue tends to become fibrotic and less responsive to medication, at which point surgery is the usual option.27Breast Care. Gynecomastia – Conservative and Surgical Management Surgical correction generally produces good cosmetic results and remains the most common definitive treatment for bothersome cases.28PubMed Central. Gynecomastia – evaluation and current treatment options
Male breast cancer treatment is, unsurprisingly, more involved. Because most male breast tumors are hormone-receptor positive, tamoxifen also plays a role here, but in a completely different context: as adjuvant endocrine therapy after surgery, typically for five years. The American Society of Clinical Oncology guideline recommends tamoxifen as the first-line endocrine option for men with hormone-receptor-positive breast cancer. Men who tolerate it well and still carry a high risk of recurrence may continue for an additional five years. For those who cannot take tamoxifen, a combination of a hormone-suppressing injection with an aromatase inhibitor is an alternative.29Journal of Clinical Oncology. Management of Male Breast Cancer: ASCO Guideline Side effects are common: about half of men on tamoxifen reported some form of toxicity, most often hot flashes, with decreased libido, weight gain, and fatigue also mentioned. Roughly one in four discontinued tamoxifen because of side effects.30PubMed Central. Endocrine therapy for male breast cancer: rates of toxicity and adherence
Why Men Delay Seeking Help
One of the most consequential real-world problems is that men wait too long to have a breast lump evaluated. A study that interviewed male breast cancer patients found that more than 90% experienced embarrassment when they first noticed symptoms. All of those men admitted the embarrassment made them hesitate before seeing a doctor.31PubMed Central. Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer The culture surrounding breast cancer is heavily coded as female: pink ribbons, awareness campaigns aimed at women, screening programs built around mammography for women over 40. Men tend to view breast tissue as irrelevant to them, and even when they find a lump, many dismiss it as unimportant because it does not hurt.
This delay matters for outcomes. Male breast cancer mortality has declined over recent decades, but less so than female breast cancer mortality, partly because men are more likely to present at a later stage.32Journal of Clinical Oncology. Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer A survey of men with various breast conditions found widespread feelings of anxiety, embarrassment, and even depression regardless of whether the diagnosis was benign or malignant.33PubMed Central. Psychological impact of male breast disorders: literature review and survey results Normalizing the idea that men can and do develop breast conditions, both benign and otherwise, would likely shorten the delay between symptom onset and diagnosis.
Environmental Chemicals and Male Breast Tissue
An emerging area of research concerns endocrine-disrupting chemicals, substances in the environment that can mimic estrogen or block androgens. A systematic review found that these chemicals represent a meaningful environmental risk factor for male breast development, essentially gynecomastia triggered by external hormone-like exposures rather than internal hormonal shifts.34PubMed Central. Potential association between endocrine disrupting chemicals (EDCs) and gynecomastia: a systematic review based on partial experimental evidence
Some of the most concrete evidence involves essential oils. Lab studies identified components of both tea tree oil and lavender oil that activate estrogen receptors. In a clinical case series, 11 of 19 boys seen with prepubertal gynecomastia reported exposure to household or personal care products containing lavender. In one case, a boy who had been exposed to lavender oil daily from birth developed breast enlargement at age 4; within six months of stopping the oil, the gynecomastia resolved and did not return.35Reproduction. The male mammary gland: a novel target of endocrine-disrupting chemicals These are small case series, not large-scale proof, but the pattern of onset with exposure and resolution after removal is consistent enough to warrant caution, especially with regular use in young boys. Whether environmental estrogen mimics play any role in male breast cancer risk is far less established and remains largely theoretical at this point.